INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide with steadily increasing mortality rates \[[@R1], [@R2]\]. In recent years, lifestyle changes including high-fat diet, lack of exercise and mental stress has resulted in a rise in CRC cases \[[@R3]\]. Radical surgery still remains the best therapeutic option for CRC patients \[[@R4]\]. However, high recurrence and metastasis rates have resulted in poor overall survival of CRC patients \[[@R5], [@R6]\]. Therefore, identification of novel prognostic risk factors is necessary for improving survival rates.

In recent years, tumor biomarkers have been widely used in clinical diagnosis, post-operative monitoring of tumor recurrence, prognosis and curative therapy of CRC patients \[[@R7]\]. The serum carcinoembryonic antigen (CEA) is one of the tumor biomarkers used for predicting recurrence, prognosis and therapeutic efficacy in CRC patients \[[@R8], [@R9]\]. The potential clinical use of changes in pre-operative and post-operative CEA levels (pre-post-CEA) has been recognized in few cancer studies \[[@R10], [@R11]\]. Increased serum CEA levels were observed after radical surgery in some patients \[[@R12], [@R13]\]. The significance of pre- and post-operative CEA levels is controversial. Hotta *et al*. reported that the pre-post-CEA ratio is prognostic predictor after surgery for stage III rectal cancer patients \[[@R10]\]. However, another study reported that post-operative serum CEA (post-CEA) levels were more definitive as prognostic prediction than pre-post-CEA ratios in non-small cell lung cancer patients. Therefore, in this study, we explored the prognostic relevance of pre-post-CEA ratios in predicting the survival time of CRC patients after radical surgery.

RESULTS {#s2}
=======

Selection strategy of research objects {#s2_1}
--------------------------------------

After screening 2833 CRC patients, we excluded the following: (1) unresectable (628 cases); (2) combined with other cancers (27 cases); (3) benign disease (94 cases); (4) pregnancy (2 cases); (5) emergency (24 cases) and (6 cases) untreatable due to widespread metastasis (23 cases). Finally, we enrolled 2035 patients including 1138 males and 897 females; of these, 872 had colon cancer and 1163 had rectal cancer (Figure [1](#F1){ref-type="fig"}).

![Scheme of selecting research subjects\
After screening 2833 CRC cases for eliminating criteria including unresectable tumors, combined with other cancers, benign disease, pregnancy, emergency and widespread metastasis, 2035 CRC cancer patients were chosen for the study.](oncotarget-08-54672-g001){#F1}

Univariate analysis of correlation between pre-CEA levels and pre-post-CEA ratios with clinicopathological parameters of CRC patients {#s2_2}
-------------------------------------------------------------------------------------------------------------------------------------

The patients were divided into low and high expression groups based on pre-CEA levels and pre-post-CEA ratios based on their mean values. Univariate analysis showed that pre-CEA levels were associated with smoking, tumor size, lymphatic and distant metastases and TNM stage (*P* \< 0.05 for all parameters; Table [1](#T1){ref-type="table"}). The pre-post-CEA ratios were associated with distant metastasis and degree of tumor differentiation (both *P* \< 0.05; Table [1](#T1){ref-type="table"}). Pre-CEA levels were not associated with gender, age, family history, tissue type, degree of tumor differentiation and tumor location. Meanwhile, pre-post-CEA ratios were not associated with gender, age, family history, smoking, tumor size, lymphatic metastasis, TNM stage, tissue type and tumor location (all *P* \> 0.05).

###### Univariate analysis of relationship between pre-CEA levels and pre-post-CEA ratios with clinicopathological parameters of CRC patients

  Clinicopathologic characteristics   *n*    Pre-CEA expression   X^2^   *P* value   Pre-post-CEA ratio   X^2^   *P* value            
  ----------------------------------- ------ -------------------- ------ ----------- -------------------- ------ ----------- -------- ----------
  **Gender**                                                             0.85        0.357                                   1.381    0.240
   Male                               1138   467                  671                                     303    863                  
   Female                             897    350                  547                                     206    663                  
  **Age (Years)**                                                        5.562       0.180                                   0.005    0.943
   ≥ 60                               1091   412                  679                                     250    737                  
   \< 60                              944    405                  539                                     264    784                  
  **Family history**                                                     3.504       0.610                                   0.839    0.36
   Yes                                173    81                   92                                      68     179                  
   No                                 1862   736                  1126                                    444    1344                 
  **Smoking**                                                            4.016       0.045                                   0.508    0.476
   Yes                                426    153                  273                                     122    337                  
   No                                 1609   664                  945                                     393    1183                 
  **Tumor size (cm)**                                                    4.509       0.034                                   0.624    0.429
   ≥ 5 cm                             1288   378                  622                                     273    832                  
   \< 5 cm                            817    439                  596                                     244    686                  
  **Lymphatic metastasis**                                               5.554       0.018                                   0.200    0.655
   Yes                                964    361                  603                                     238    687                  
   No                                 1071   456                  615                                     276    834                  
  **Distant metastasis**                                                 179.119     \< 0.001                                40.936   \<0.001
   Yes                                615    111                  504                                     140    224                  
   No                                 1420   706                  714                                     374    1297                 
  **TNM stage**                                                          90.384      \< 0.001                                1.220    0.269
   I/II                               641    355                  286                                     243    760                  
   III/IV                             1394   462                  932                                     272    760                  
  **Tissue type**                                                        0.32        0.858                                   0.538    0.463
   Adenocarcinoma                     1551   621                  930                                     424    1279                 
   Non-adenocarcinoma                 484    196                  288                                     89     243                  
  **General tumor type**                                                 0.093       0.76                                    0.516    0.473
   Ulcerative                         1174   468                  706                                     289    885                  
   Non-ulcerative                     861    349                  512                                     224    637                  
  **Differentiation degree**                                             2.344       0.120                                   40.037   \< 0.001
   High/Median                        1291   502                  789                                     326    1187                 
   Low/undifferentiated               744    315                  429                                     188    334                  
  **Tumor location**                                                     1.43        0.232                                   2.389    0.122
   Colon                              872    337                  535                                     234    595                  
   Rectum                             1163   480                  683                                     379    827                  

Multivariate analysis of the correlation between pre-CEA levels and pre-post-CEA ratios with clinicopathological parameters of CRC patients {#s2_3}
-------------------------------------------------------------------------------------------------------------------------------------------

Multivariate analysis showed that pre-CEA levels were associated with family history, smoking, tumor size, distant metastasis and TNM stages (all *P* \< 0.05; Table [2](#T2){ref-type="table"}). However, they were not associated with other cancer in combination, lymphatic metastasis, tissue type, general tumor type, degree of tumor differentiation and tumor location (all *P* \> 0.05). Meanwhile, pre-post-CEA ratios were associated with lymphatic and distant metastases, TNM stage and degree of tumor differentiation (all *P* \< 0.01; Table [2](#T2){ref-type="table"}). But, they were not associated with family history, smoking, other cancer in combination, tumor size, tissue type, general tumor type and tumor location (all *P* \> 0.05).

###### Multivariate analysis of relationship between pre-operative CEA and pre- to post-operative CEA with clinicopathological parameters of CRC patients

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinicopathologic characteristics      Pre-operative CEA expression   Pre- to post-operative CEA ratio                                            
  -------------------------------------- ------------------------------ ---------------------------------- ------- ------- -------- ------- ------- --------
  **Tumor family history**\              4.576                          0.032                              0.494   0.970   0.476    0.490   0.715   2.014
  Yes vs. No                                                                                                                                        

  **Smoking**\                           5.072                          0.024                              1.036   1.664   0.108    0.742   0.712   1.609
  Yes vs. No                                                                                                                                        

  **Tumor size (cm)**\                   9.812                          0.002                              1.124   1.662   1.093    0.296   0.575   1.183
  ≥5cm vs. \<5cm                                                                                                                                    

  **Lymphatic metastasis**\              0.363                          0.547                              0.598   1.313   20.017   0.000   2.330   8.708
  Yes vs. No                                                                                                                                        

  **Distant metastasis**\                63.108                         0.000                              2.423   4.326   28.176   0.000   2.284   6.006
  Yes vs. No                                                                                                                                        

  TNM stages\                            9.087                          0.003                              0.331   0.791   28.445   0.000   3.320   13.384
  I/II vs. III/IV                                                                                                                                   

  **Tissue type**\                       0.099                          0.753                              0.789   1.388   0.051    0.821   0.594   1.512
  Adenocarcinoma\                                                                                                                                   
  vs.\\\                                                                                                                                            
  Non-adenocarcinoma                                                                                                                                

  **Tumor general type**\                0.684                          0.408                              0.877   1.383   3.792    0.051   0.498   1.002
  Ulcerative vs. Non-ulcerative                                                                                                                     

  **Differentiation degree**\            1.077                          0.299                              0.904   1.388   10.381   0.001   0.353   0.776
  High/Median vs. Low/undifferentiated                                                                                                              

  **Tumor location**\                    0.010                          0.919                              0.811   1.208   1.378    0.241   0.869   1.754
  Colon vs. Rectum                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

Univariate analysis of the correlation between pre-CEA levels and pre-post-CEA ratios with 5-year OS {#s2_4}
----------------------------------------------------------------------------------------------------

As shown in Table [3](#T3){ref-type="table"}, univariate analysis demonstrated that pre-CEA levels, pre-post-CEA ratios, tumor size, TNM stage, lymphatic metastasis, distant metastasis and degree of tumor differentiation were associated with 5-year overall survival (OS, all *P* \< 0.05). Factors like age, gender, family history, smoking, tissue type and tumor location were not related with 5-year OS (all *P* \> 0.05).

###### Univariate analyses of correlation between clinicopathological parameters and 5-year OS of CRC patients

  Clinicopathologic characteristics   *n*    5-year OS   X^2^      *P* value
  ----------------------------------- ------ ----------- --------- -----------
  **Gender**                                             0.384     0.535
   Male                               1138   72.2%                 
   Female                             897    66.7%                 
  **Age (Years)**                                        0.046     0.831
   ≥ 60                               1091   69.5%                 
   \< 60                              944    69.9%                 
  **Family history**                                     0.000     0.997
   Yes                                173    68.3%                 
   No                                 1862   69.7%                 
  **Smoking**                                            10282     0.258
   Yes                                426    75.4%                 
   No                                 1609   67.8%                 
  **Pre-CEA levels**                                     13.849    \< 0.001
   high                               1218   60%                   
   low                                817    79.1%                 
  **Pre-post-CEA ratio**                                 14.513    \< 0.001
   Low                                578    62.8%                 
   High                               195    72%                   
  **Tumor size (cm)**                                    5.526     0.019
   ≥ 5 cm                             945    60.7%                 
   \< 5 cm                            990    76.1%                 
  **Lymphatic metastasis**                               6.353     0.012
   Yes                                1024   64.2%                 
   No                                 1011   72%                   
  **Distant metastasis**                                 122.546   \< 0.001
   Yes                                615    27.4%                 
   No                                 1420   78.2%                 
  **TNM stage**                                          4.781     0.029
   I/II                               641    71.6%                 
   III/IV                             1394   65.2%                 
  **Tissue type**                                        0.858     0.354
   Adenocarcinoma                     1551   69.5%                 
   Non-adenocarcinoma                 484    70.1%                 
  **Tumor general type**                                           
   Ulcerative                         1174   67.4%       0.976     0.269
   Non-ulcerative                     861    71.2%                 
  **Differentiation degree**                             6.238     0.013
   High/Median                        1291   70.4%                 
   Low/undifferentiated               744    64.5%                 
  **Tumor location**                                     0.026     0.872
   Colon                              872    71.8%                 
   Rectum                             1163   68.3%                 

Multivariate analysis of the correlation between pre-CEA levels and pre-post-CEA ratios with 5-year OS {#s2_5}
------------------------------------------------------------------------------------------------------

Multivariate survival analysis showed that pre-operative CEA, pre- to post- operative CEA ratio, distant metastasis, TNM stage and degree of tumor differentiation were associated with 5-year OS (all *P* \< 0.05, Table [4](#T4){ref-type="table"}). Meanwhile, gender, age, family history, smoking, tumor size, lymphatic metastasis, tissue type, general tumor type and tumor location were not associated with 5-year OS (all *P* \> 0.05, Table [4](#T4){ref-type="table"}). Therefore, our analysis demonstrated that pre-CEA levels, pre-post-CEA ratios, distant metastasis, TNM stage and differentiation degree were independent risk factors for 5-year OS of CRC patients.

###### COX regression survival analyses of clinicopathological parameters of CRC patients

  --------------------------------------------------------------------------------------------
  Clinicopathological characteristics   RR       *P* value   95% confidence interval   
  ------------------------------------- -------- ----------- ------------------------- -------
  **Gender**\                           0.591    0.442       0.786                     1.738
  Male vs. Female                                                                      

  **Age (Years)**\                      2.536    0.111       0.511                     1.072
  ≥ 60 vs. \< 60                                                                       

  **Tumor family history**\             0.043    0.835       0.618                     1.815
  Yes vs. No                                                                           

  **Smoking**\                          0.046    0.831       0.636                     1.758
  Yes vs. No                                                                           

  **Pre-CEA**\                          7.897    0.005       0.351                     0.830
  ≥ 5 vs. \< 5                                                                         

  **Pre-post-CEA**\                     5.434    0.020       0.390                     0.922
  Low vs. High                                                                         

  **Tumor size (cm)**\                  2.581    0.108       0.485                     1.074
  ≥ 5 cm vs. \< 5 cm                                                                   

  **Lymphatic metastasis**\             0.093    0.761       0.512                     1.631
  Yes vs. no                                                                           

  **Distant metastasis**\               28.112   0.000       0.177                     0.451
  Yes vs. no                                                                           

  **TNM stage**\                        4.420    0.036       1.054                     4.540
  I/II vs. III/IV                                                                      

  **Tissue type**\                      0.568    0.451       0.471                     1.398
  Adenocarcinoma\                                                                      
  vs. Non-adenocarcinoma                                                               

  **Tumor general type**\               1.640    0.200       0.884                     1.801
  Ulcerative vs. Non-ulcerative                                                        

  **Differentiation degree**\           10.181   0.001       1.272                     2.741
  High/Median\                                                                         
  vs. Low/undifferentiated                                                             

  **Tumor location**\                   0.003    0.959       0.697                     1.463
  Colon vs. Rectum                                                                     
  --------------------------------------------------------------------------------------------

Kaplan-Meier analysis of association of overall survival with pre-CEA levels and pre-post-CEA ratios {#s2_6}
----------------------------------------------------------------------------------------------------

Kaplan-Meier survival curve analysis showed that overall survival decreased post-operatively (Figure [2](#F2){ref-type="fig"}). Interestingly, patients with low pre-CEA levels demonstrated survived longer than those with high pre-CEA levels (log-rank test, *P* \< 0.001; Figure [3](#F3){ref-type="fig"}). Meanwhile, patients with a lower pre-post-CEA ratios survived longer compared to those with higher pre-post-CEA ratios (log-rank test, *P* \< 0.001; Figure [4](#F4){ref-type="fig"}). Also, patients with low pre-CEA levels and pre-post-CEA ratios (group 1) showed longer survival than patients with high pre-CEA levels and pre-post-CEA ratios (group 2). However, patients with lower pre-CEA levels, but high pre-post-CEA ratios (group 3) and patients with higher pre-CEA levels and low pre-post-CEA ratios (group 4) showed no differences with overall survival (log-rank test, *P* \> 0.05). Also, patients in groups 3 and 4 showed lower OS than group 1 patients and higher OS than group 2 patients (log-rank test, both *P* \> 0.05; Figure [5](#F5){ref-type="fig"}). This suggested that the pre-CEA levels and pre-post-CEA ratios had a synergistic effect in prognostic prediction of overall survival of CRC patients.

![Kaplan-Meier survival curve of enrolled CRC patients\
The Kaplan-Meier survival plot shows decreasing overall survival with post-operative time (months).](oncotarget-08-54672-g002){#F2}

![Kaplan-Meier survival curves of CRC patients based on pre-operative CEA levels\
Overall survival of CRC patients with high (red) and low (blue) pre-operative CEA levels compared to total (green) CRC patients based on Kaplan-Meier curves and log-rank test. As shown, patients with low pre-CEA levels survived longer than those with high pre-CEA levels (log-rank test, *P* \< 0.001).](oncotarget-08-54672-g003){#F3}

![Kaplan-Meier survival curves of CRC patients based on pre-post-CEA ratios\
Overall survival of CRC patients with low (blue) and high (red) pre-post-CEA ratios compared to total (gray) number of CRC patients based Kaplan-Meier curves and log rank test. As shown, patients with low pre-post-CEA ratios survived longer than those with high pre-post-CEA ratios (log-rank test, *P* \< 0.001).](oncotarget-08-54672-g004){#F4}

![Kaplan-Meier survival curve analysis of different combinations of pre-CEA levels and pre-post-CEA ratios\
CRC patients with low pre-CEA levels plus low pre-post-CEA ratio (blue) survived longer than those with high pre-CEA levels plus high pre-post-CEA ratios (red). CRC patients with low pre-CEA levels plus high pre-post-CEA ratios (green) and those with high pre-CEA levels plus low pre-post-CEA ratios (gray) show comparable survival rates (log-rank test, *P* \> 0.05) and are intermediate in comparison to the previous two groups (log-rank test, all *P* \> 0.05).](oncotarget-08-54672-g005){#F5}

DISCUSSION {#s3}
==========

Carcino-embryonic antigen (CEA) represents a group of macromolecular acid glycoproteins expressed highly during fetal development and reduced in the adults \[[@R14], [@R15]\]. High CEA levels were first observed in colorectal cancer and then in other malignant tumors of the esophagus, stomach, liver and pancreas \[[@R16], [@R17]\]. CEA is secreted by cancer cells resulting in high serum CEA levels.

Many studies have suggested that CEA levels can be used for predicting metastasis although few contradictory reports exist \[[@R18]--[@R20]\]. High CEA levels are observed in cancers, whereas changes are also observed in smoking, inflammation, pregnancy, gynecological disease and hepatitis conditions \[[@R21], [@R22]\]. Furthermore, prognostic potential of pre-post-CEA ratio has been reported for CRC patients. In gastric cancer, elevated pre-operative CK19 and CEA mRNA levels were associated with lymph node metastasis and predicted poor prognosis \[[@R22]\]. Yang *et al*. also reported that elevated pre- and post-operative serum CEA levels were associated with recurrence and poor clinical outcomes in few CRC patients \[[@R23]\]. Duan *et al* showed that high serum CEA or CYFRA 21-1 levels before and after surgery were associated with poor overall survival (OS) and progress-free survival (PFS) in stage I non-small cell lung cancer \[[@R11]\]. In this study, we explored the prognostic significance of pre-post-CEA ratios for CRC patients. We observed that pre-post-CEA ratios were closely related with smoking, tumor size, lymph node and distant metastases and post-operative pathological TNM staging. Also, our analysis demonstrated that distant metastasis and post-operative TNM stage were independent risk factors along with pre-CEA levels and pre-post-CEA ratios, consistent with previous reports.

Lymph node metastasis \[[@R24]\] and distant metastasis, particularly liver \[[@R25], [@R26]\] are independent risk factors with pre-CEA levels for CRC. The cell recognition, adhesion and immunosuppressive properties of CEA, which are Ca2+ dependent cell adhesion molecules aids aggregation, adhesion, invasion and metastasis of tumor cells \[[@R27], [@R28]\]. Therefore, excessive serum CEA levels are beneficial to CRC metastasis. Our study also demonstrated that lymphatic and distant metastases were independent risk factors in advanced stage III and IV CRC.

In previous studies, pre-CEA levels were identified as reliable indicators of prognosis and therapeutic efficacy in stage II and III CRC patients \[[@R18], [@R29]\]. Many studies also reported that pre-CEA levels were an independent risk factor for CRC patients \[[@R18], [@R30]--[@R31]\]. Our study further confirmed that pre-CEA level was an independent prognostic factor. Therefore, pre-CEA levels can be used evaluate therapeutic efficacy, post-operative tumor recurrence and predict prognosis of CRC patients.

Apart from the prognostic value of pre-CEA levels, few studies have also reported the prognostic value of pre-operative and post-operative CEA levels in combination \[[@R10]\]. Therefore, we analyzed the significance of pre-post-CEA ratios and found that it was associated with lymphatic and distant metastases and post-operative pathological TNM stage. These three indicators were also shown to be independent risk factors along with pre-post-CEA ratios.

Based on tumor source, the degree of malignancy determined by histology has been used to classify different pathological types of tumors \[[@R32], [@R33]\]. Most CRC patients are associated with moderately differentiated tumors, whereas high CEA levels are associated with poorly differentiated or undifferentiated CRC that are highly malignant \[[@R34]\]. In our study, pre-operative serum CEA levels were higher in lowly differentiated and undifferentiated carcinomas. Further, the differentiation degree of tumors affected the pre-post-CEA ratios in CRC patients. CEA is an important risk factor affecting CRC prognosis \[[@R13]\]. We observed that patients with decreasing post-operative CEA demonstrated better prognosis than those with higher post-operative CEA. Therefore, pre-post-CEA ratio is potentially an important prognostic marker.

During malignant transformation of CRC cells, overexpression of CEA lowers the function of other adhesion molecules and interferes in the interaction between normal cells, thereby weakening the single-layer structure of glandular tube \[[@R27]--[@R35], [@R36]\]. Therefore, excessive CEA in combination with genetic damage would promote malignancy of tumors. According to the NCCN guidelines, CRC of TNM stages 3 and 4 are accompanied by lymphatic and distant metastases, severely damaged colon tissues and CEA overexpression. Therefore, high pre-CEA levels and lymphatic or distant metastases were used as prognostic indicators and lymph node or micro-distant metastasis was neglected during surgery \[[@R37]\]. After surgery, post-CEA levels would increase leading to high pre-post-CEA ratios. In our study, pre-post-CEA ratio was closely related with lymphatic and distant metastases, TNM stage and degree of tumor differentiation, consistent with previous reports.

There is consensus that lymphatic metastasis, distant metastasis and TNM stage dictate prognostic status of CRC patients. In our study, these three indicators were also independent risk factors in relation to for pre-post-CEA ratios. Therefore, pre-post-CEA ratios are an essential risk factor for prognosis of CRC patients.

In conclusion, pre-post-CEA ratios were associated with the malignant phenotype of lymphatic metastasis, distant metastasis, TNM stage and degree of tumor differentiation in CRC patients. It was also an independent risk factor for CRC patients. Therefore, we postulate that pre-post-CEA ratio is a potential tumor biomarker to evaluate prognosis and therapeutic efficacy in CRC patients.

MATERIALS AND METHODS {#s4}
=====================

Patients and clinicopathological parameters {#s4_1}
-------------------------------------------

This study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (No.ZZUF-2016174). All patients provided informed written consent prior to their participation. Clinicopathological parameters and follow-up data were obtained 2035 CRC patients (1138 male, 897 female) that received radical surgery in the First Affiliated Hospital of Zhengzhou University between June 2001 and June 2011. The mean patient age was 59.84+13.44 years. Among the 2035 CRC patients, 872 had colon cancer and 1163 rectal cancers. Colon cancer diagnosis was confirmed by histopathology prior to their participation. None of the enrolled patients received pre-operative chemotherapy or immunotherapy. Tumor-node-metastasis (TNM) stage was determined according to the American Joint Committee on Cancer/International Union Against Cancer TNM staging system of colorectal cancer (2010, 7th edition).

Enzyme linked immunosorbent assay (ELISA) assay {#s4_2}
-----------------------------------------------

Blood samples (4ml each) were obtained within the week before surgery for preoperative CEA estimation and 1--2 weeks after the surgery for post-operative CEA estimation. Serum CEA levels were estimated by ELISA kit (ab183365, Abcam, England) according to manufacturer\'s instructions.

Patient follow-up {#s4_3}
-----------------

After surgery, the patients were assessed once a month for the first 6 months, once every 3 months for the first 2 years, once every 6 months until 5 years followed by once a year. Follow-ups were either by outpatient or inpatient review or by telephone. 216 patients did not participate in the follow-up analyses because they did not communicate with the physicians after surgery. In addition, 13 patients developed dysthymia and were unable to cooperate with the study; 3 patients committed suicide and 19 patients did not participate in the follow-up for unknown reasons. Therefore, the total follow-up rate in the study was 87.67%.

Chemotherapy and radical surgery {#s4_4}
--------------------------------

FOLFOX6 was used as the first line adjuvant or neoadjuvant therapy scheme for CRC patients with high-risk IInd or IIIrd stage. CapeOX was used as the chemotherapy scheme as either 1st or 2nd line adjuvant or neoadjuvant therapy for CRC patients with high-risk IInd, IIIrd or IVth stage, drug resistance or postoperative recurrence. FOLFIRI was used as the chemotherapy scheme for CRC patients in advanced IVth stage, postoperative recurrence, metastasis or drug resistance.

Radical surgery was performed according to complete mesocolic excision (CME) for colon cancer patients and total mesorectal excision (TME) principle for rectal cancer patients.

Statistical analysis {#s4_5}
--------------------

All statistical analyses were carried out using SPSS for Windows version 20 (SPSS Inc., Chicago, IL, United States). Univariate analysis was performed by χ^2^ test to analyze pre-CEA levels and pre-post-CEA ratios and clinicopathological parameters. Kaplan Meier survival curves and log-rank test were used to compare the low and high level groups of pre-CEA levels and pre-post-CEA ratios. Multivariate survival analysis was performed by the Cox regression model to determine relative risk (RR) and 95% confidence intervals (CI). Statistical significance was defined as *P* \< 0.05.
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